New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

23

FDA Grants EUA to Combination of Olumiant and Remdesivir in Hospitalized Covid-19 Patients

The U.S. Food and Drug Administration granted Emergency Use Authorization to a combination of Eli Lilly’s and Incyte’s rheumatoid arthritis drug Olumiant (baricitinib) and Gilead Sciences’ remdesivir as a treatment for hospitalized patients diagnosed with Covid-19 who require supplemental oxygen or ventilation.